Patents by Inventor Daniël VERHOEF

Daniël VERHOEF has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROHEMOSTATIC PROTEINS FOR THE TREATMENT OF BLEEDING
    Publication number: 20220288172
    Abstract: Described are recombinant FXa polypeptides that can be used as antidotes to completely or partially reverse an anti-coagulant effect of a coagulation inhibitor in a subject, preferably a direct factor Xa inhibitor. Disclosed herein are recombinant factor Xa proteins and a method of completely or partially reversing an anti-coagulant effect of a coagulation inhibitor in a subject.
    Type: Application
    Filed: May 31, 2022
    Publication date: September 15, 2022
    Inventors: Daniël Verhoef, Pieter H. Reitsma, Mettine H. A. Bos
  • Prohemostatic proteins for the treatment of bleeding
    Patent number: 11357836
    Abstract: This disclosure relates to recombinant FXa polypeptides that can be used as antidotes to completely or partially reverse an anti-coagulant effect of a coagulation inhibitor in a subject, preferably a direct factor Xa inhibitor. Disclosed herein are recombinant factor Xa proteins and a method of completely or partially reversing an anti-coagulant effect of a coagulation inhibitor in a subject.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: June 14, 2022
    Assignee: Academisch Ziekenhuis Leiden
    Inventors: Daniël Verhoef, Pieter H. Reitsma, Mettine H. A. Bos
  • Prohemostatic proteins for the treatment of bleeding
    Patent number: 11304995
    Abstract: This disclosure relates to recombinant FXa polypeptides that can be used as antidotes to completely or partially reverse an anti-coagulant effect of a coagulation inhibitor in a subject, preferably a direct factor Xa inhibitor. Disclosed herein are recombinant factor Xa proteins and a method of completely or partially reversing an anti-coagulant effect of a coagulation inhibitor in a subject.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: April 19, 2022
    Assignee: Academisch Ziekenhuis Leiden
    Inventors: Daniël Verhoef, Pieter H. Reitsma, Mettine H. A. Bos
  • PROHEMOSTATIC PROTEINS FOR THE TREATMENT OF BLEEDING
    Publication number: 20200138916
    Abstract: This disclosure relates to recombinant FXa polypeptides that can be used as antidotes to completely or partially reverse an anti-coagulant effect of a coagulation inhibitor in a subject, preferably a direct factor Xa inhibitor. Disclosed herein are recombinant factor Xa proteins and a method of completely or partially reversing an anti-coagulant effect of a coagulation inhibitor in a subject.
    Type: Application
    Filed: December 18, 2019
    Publication date: May 7, 2020
    Inventors: Daniël Verhoef, Pieter H. Reitsma, Mettine H. A. Bos
  • PROHEMOSTATIC PROTEINS FOR THE TREATMENT OF BLEEDING
    Publication number: 20200138917
    Abstract: This disclosure relates to recombinant FXa polypeptides that can be used as antidotes to completely or partially reverse an anti-coagulant effect of a coagulation inhibitor in a subject, preferably a direct factor Xa inhibitor. Disclosed herein are recombinant factor Xa proteins and a method of completely or partially reversing an anti-coagulant effect of a coagulation inhibitor in a subject.
    Type: Application
    Filed: December 18, 2019
    Publication date: May 7, 2020
    Inventors: Daniël Verhoef, Pieter H. Reitsma, Mettine H. A. Bos
  • Prohemostatic proteins for the treatment of bleeding
    Patent number: 10537618
    Abstract: This disclosure relates to recombinant FXa polypeptides that can be used as antidotes to completely or partially reverse an anti-coagulant effect of a coagulation inhibitor in a subject, preferably a direct factor Xa inhibitor. Disclosed herein are recombinant factor Xa proteins and a method of completely or partially reversing an anti-coagulant effect of a coagulation inhibitor in a subject.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: January 21, 2020
    Assignee: ACADEMISCH ZIEKENHUIS LEIDEN
    Inventors: Daniël Verhoef, Pieter H. Reitsma, Mettine H. A. Bos
  • RECOMBINANT SERINE PROTEASES
    Publication number: 20180340163
    Abstract: The present invention relates to recombinant proteins having serine protease polypeptides that have serine protease activity in the presence of a serine protease inhibitor and that are able to completely or partially reverse a serine protease inhibitor effect, for example in a subject treated with a serine protease inhibitor. More specifically, described herein are recombinant proteins and methods for completely or partially reversing an anti-coagulant effect of a coagulation inhibitor.
    Type: Application
    Filed: November 25, 2016
    Publication date: November 29, 2018
    Inventors: Daniel VERHOEF, Pieter H REITSMA, Mettine H.A. BOS
  • PROHEMOSTATIC PROTEINS FOR THE TREATMENT OF BLEEDING
    Publication number: 20170157223
    Abstract: This disclosure relates to recombinant FXa polypeptides that can be used as antidotes to completely or partially reverse an anti-coagulant effect of a coagulation inhibitor in a subject, preferably a direct factor Xa inhibitor. Disclosed herein are recombinant factor Xa proteins and a method of completely or partially reversing an anti-coagulant effect of a coagulation inhibitor in a subject.
    Type: Application
    Filed: May 26, 2015
    Publication date: June 8, 2017
    Inventors: Daniël VERHOEF, Pieter H. REITSMA, Mettine H. A. BOS